Viridian Therapeutics, Inc.\DE (VRDN) Times Interest Earned (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Times Interest Earned of -$33.56 for Q1 2026, up 80.34% year-over-year from -$18.61 in Q1 2025, and up 1.97% quarter-over-quarter from -$34.23 in Q4 2025.
Powered by 
Analysis
Viridian Therapeutics, Inc.\DE (VRDN) Times Interest Earned (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Times Interest Earned history runs 14 years deep, the most recent figure standing at -$33.56 for Q1 2026.
- In Q1 2026, Times Interest Earned rose 80.34% year-over-year to -$33.56; the TTM figure through Mar 2026 stood at -$47.28 (up 76.33% YoY), while the FY2025 annual figure was -$1.15, up 20.02% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$33.56, up from -$34.23 in the prior quarter.
- The five-year high for Times Interest Earned was $7009.4 in Q4 2022, with the low at -$624.8 in Q4 2024.
- The 5-year median for Times Interest Earned is -$103.14 (2024), against an average of $287.14.
- The sharpest annual moves came in 2022 and 2025: Times Interest Earned soared 4920.62% in 2022, then sank 1228.72% in 2025.
- Viridian Therapeutics, Inc.\DE's Times Interest Earned stood at $7009.4 in 2022, then tumbled by 102.55% to -$178.7 in 2023, then tumbled by 249.65% to -$624.8 in 2024, then jumped by 94.52% to -$34.23 in 2025, then gained by 1.97% to -$33.56 in 2026.
- Business Quant data shows VRDN's Times Interest Earned at -$33.56 in Q1 2026, -$34.23 in Q4 2025, and -$71.45 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Viridian Therapeutics, Inc.\DE | 2.42 Bn | 2.42 Bn | - | -15.20 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.20 |
| Mar 31, 2026 | -33.56 |
| Dec 31, 2025 | -37.40 |
| Sep 30, 2025 | -71.45 |
| Jun 30, 2025 | -207.72 |
| Mar 31, 2025 | -170.67 |
| Dec 31, 2024 | -169.19 |
| Sep 30, 2024 | -157.81 |
| Jun 30, 2024 | -120.92 |
| Mar 31, 2024 | -95.22 |
| Dec 31, 2023 | -178.70 |
| Sep 30, 2023 | -85.37 |
| Jun 30, 2023 | -357.08 |
| Mar 31, 2023 | -439.23 |
| Dec 31, 2022 | -292.06 |
| Sep 30, 2022 | -181.62 |
| Jun 30, 2022 | -191.97 |
| Dec 31, 2021 | -9,693.67 |
| Dec 31, 2020 | -503.32 |
| Sep 30, 2020 | -58.17 |